Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

<p>Initial results show promising clinical activity in heavily pretreated patients 22 patients evaluable for efficacy: 3 patients on therapy longer than 10 months, 1 patient longer than 6 months, and 5 patients longer than 4 months 19 patients with measurable disease by RANO criteria: 1 patient with confirmed partial response and 8 patients with stable [&#8230;]</p>
<p>The post <a href="https://forextv.com/top-news/black-diamond-therapeutics-announces-topline-results-from-phase-1-dose-escalation-trial-of-bdtx-1535-in-patients-with-recurrent-gbm/">Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>